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Edited by Gianni CesareniAbstract We studied the RNA aptamer Toggle-25/throm-
bin interaction during inhibition by antithrombin (AT), heparin
cofactor II (HCII) and protein C inhibitor (PCI). Thrombin
inhibition was reduced 3-fold by Toggle-25 for AT and HCII, but
it was slightly enhanced for PCI. In the presence of glycosami-
noglycans, AT and PCI had signiﬁcantly reduced thrombin
inhibition with Toggle-25, but it was only reduced 3-fold for
HCII. This suggested that the primary eﬀect of aptamer binding
was through the heparin-binding site of thrombin, anion-binding
exosite-2 (exosite-2). We localized the Toggle-25 binding site to
Arg 98, Glu 169, Lys 174, Asp 175, Arg 245, and Lys 248 of
exosite-2. We conclude that a RNA aptamer to thrombin
exosite-2 might provide an eﬀective clinical reagent to control
heparin’s anticoagulant action.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Numerous proteases, protease inhibitors, cofactors and cells
control the physiological process of hemostasis [1,2]. The he-
mostatic balance is disrupted either when an injury occurs or
when a pathological process leads to underproduction (hem-
orrhage) or overproduction (thrombosis) of thrombin activity.
Thrombosis accounts for signiﬁcant morbidity and mortality in
conditions such as deep venous thrombosis with pulmonary
embolism, acute coronary syndrome, stroke, and peripheral
vascular disease [3]. Hemostatic proteases are obvious targets
for anticoagulants and antithrombotics. The anticoagulant
heparin is believed to act by accelerating thrombin and factor
Xa inhibition by binding to antithrombin (AT; systematic name
SERPINC1) and other heparin-dependent serine protease in-
hibitors (serpins) [4,5]. However, heparin has potentially lethal* Corresponding author. Fax: +1-919-966-7639.
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tor II; AT, antithrombin; PCI, protein C inhibitor; exosite-1 and -2,
anion-binding exosite-1 and anion-binding exosite-2
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doi:10.1016/j.febslet.2004.04.087side eﬀects such as bleeding and heparin-induced thrombocy-
topenia, and although protamine sulfate can be used to reverse
heparin’s anticoagulant action, it also has associated toxicities
[6]. Therefore, there is an interest for alternative therapeutic
anticoagulants to substitute for heparin and for new substances
to terminate heparin’s action as a therapeutic anticoagulant.
Thrombin is a serine protease that possesses trypsin-like
behavior in that it prefers to cleave its substrates after arginyl
residues [7–10]. Unlike trypsin, thrombin has numerous sur-
face subsites that inﬂuence macromolecular substrate interac-
tions that make it a more discriminating protease [10]. One of
these subsites is anion-binding exosite-1 (exosite-1). Thrombin
exosite-1 has been implicated in binding of ﬁbrinogen, leech
anticoagulant hirudin, protease activated receptor-1, throm-
bomodulin, factors V and VIII, glycoprotein-1ba, and the
acidic domain of the serpin heparin cofactor II (HCII;
systematic name SERPIND1). Anion-binding exosite-2 (exo-
site-2) [10] is primarily responsible for thrombin’s glycosami-
noglycan binding abilities, which helps accelerate protease
inhibition by the heparin-dependent serpins, AT, HCII, pro-
tein C inhibitor (PCI; also known as plasminogen activator
inhibitor-3; systematic name SERPINA5), and protease nexin-
1 [4,5]. The 60-insertion loop (60-loop) of thrombin forms a
lid-like structure over the catalytic triad and active site region,
and controls access of substrates and inhibitors to the active
site [10]. These subsites oﬀer unique possibilities to provide
binding sites for ligands that might modulate thrombin’s ac-
tivity, give new understanding of structure-activity relation-
ships, and generate novel anticoagulants.
DNA and RNA aptamers are one type of potential thera-
peutic agents [11,12]. RNA aptamers are made using an iter-
ative in vitro selection process called SELEX (systematic
evolution of ligands by exponential enrichment), which selects
high aﬃnity binding RNA molecule from a large pool of
random-sequence single-stranded oligonucleotide populations
[11–13]. Thrombin has been a frequent target for both DNA
and RNA-speciﬁc aptamers, both for structure-function and
therapeutic uses [14–17]. Toggle-25 is a RNA aptamer recently
described by White et al. [16]. This RNA aptamer was selected
by a technique of ‘‘toggling’’ between protein targets; thus,
Toggle-25 binds both human and porcine thrombin. Toggle-25
is made from endonuclease-resistant nucleotides, which confer
a half-life of many hours in vivo compared to minutes for
unmodiﬁed RNA or DNA aptamers. We studied the eﬀect ofblished by Elsevier B.V. All rights reserved.
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AT, HCII, and PCI in the absence and presence of glycosa-
minoglycans, and we localized the RNA aptamer-binding site
on the thrombin molecule. Based on the results of these ex-
periments, we show that a RNA aptamer directed to exosite-2
of thrombin aﬀords thrombin protection during inhibition by
heparin-binding serpins.2. Materials and methods
2.1. Proteins and reagents
Plasma derived human a-thrombin, AT, and HCII were prepared
and puriﬁed to homogeneity as described previously [18–20]. Human
wild-type recombinant PCI was expressed in Escherichia coli [strain
BL21(DE3)pLysS] using the Qiagen pET15b expression vector (with a
N-terminal polyhistidine sequence), and puriﬁed to homogeneity by
Ni2þ-chelate chromatography (Rehault, S.M. et al., 2004, un-
published). Recombinant wild-type thrombin and exosite-2 thrombin
mutants were prepared as described [21]. The following thrombin
exosite-2 mutants were studied: R89A/R93A/E94A, R98A, D122A/
R123A/E124A, E169A/K174A/D175A, R178A/R180A/D183A,
R245A/K248A/Q251A, R245A, K248A, and Q251A (residue numbers
according to the thrombin numbering system3). Unbleached crude
heparin was obtained from Diosynth (Oss, The Netherlands). Der-
matan sulfate (Calbiochem) was treated with nitrous acid to remove
contaminating heparin/heparan sulfate as detailed [22]. Toggle-25
(50-GGGAACAAAGCUGAAGUACUUACCC-30) was synthesized,
puriﬁed and deprotected as described previously [16]. The control
aptamer BulgeUs is a point mutant at nucleotides 20 and 21 (changing
UU to AA) that has no measurable aﬃnity for thrombin [16]. Both
aptamers contain a 30-inverted deoxythymidine cap to prevent exo-
nuclease degradation, and all Cs and Us contain 20-deoxyﬂuoro sugars
[16]. Both RNA aptamers were diluted to a ﬁnal concentration of 50
lM in 20 mM HEPES, 150 mM NaCl, and 2 mM CaCl2 at pH 7.4.
2.2. Serpin/thrombin inhibition assays
All assays were performed at room temperature in 96-well microtiter
plates previously coated with 2 mg/mL ovalbumin essentially as
described previously [23,24]. In the absence of glycosaminoglycan,
100–500 nM serpin (AT, HCII, or PCI) was incubated with 0.5 nM a-
thrombin in 20 mM HEPES, 150 mM NaCl, and 2 mM CaCl2 at pH
7.4, in the absence of RNA aptamer and with 10 nM Toggle-25 or
BulgeUs, all in a ﬁnal reaction volume of 50 lL. At varied time points
(5–120 min), residual thrombin activity was measured by adding 50 lL
of 450 lM tosGly-Pro-Arg-p-nitroanilide and 30 lg/mL Polybrene in
the HEPES buﬀer at pH 7.4. Substrate cleavage was measured by color
development at 405 nm on a Vmax Kinetic Microplate Reader (Mo-
lecular Devices).
In the presence of glycosaminoglycans (heparin or dermatan sulfate),
5–20 nM serpin (AT, HCII or PCI) was incubated with 0.1–2000 lg/
mL heparin or dermatan sulfate with 0.5–1 nM thrombin in 20 mM
HEPES, 150 mM NaCl, and 2 mM CaCl2 at pH 7.4, in the absence of
RNA aptamer or 10 nM Toggle-25 or BulgeUs in a ﬁnal reaction
volume of 50 lL. In all assays, the RNA aptamer was incubated for 60
s with thrombin prior to the addition of the other reactants. At varied
time incubations (15 s–25 min), 50 lL of 450 lM tosGly-Pro-Arg-p-
nitroanilide and 1–5 mg/mL Polybrene (ﬁnal concentration to imme-
diately neutralize glycosaminoglycan) was added to measure residual
thrombin activity. After allowing tosGly-Pro-Arg-p-nitroanilide
cleavage by the remaining thrombin, the reaction was stopped by
adding a 50% acetic acid solution. The plates were then spun at
1350 g for 15 min to remove the glycosaminoglycan/Polybrene pre-
cipitate that forms at high glycosaminoglycan concentrations. After
transferring 100 lL of the supernatant of each well to a new plate,3 In parentheses are the thrombin residues using the numbering
system with respect to bovine chymotrypsinogen [7,10]: R89A/R93A/
E94A (R93A/R97A/E97aA), R98A (R101A), D122A/R123A/E124A
(D125A/R126A/E127A), E169A/K174A/D175A (E164A/K169A/
D170A), R178A/R180A/D183A (R173A/R175A/D178A), R245A/
K248A/Q251A (R233A/K236A/Q239A), R245A (R233A), K248A
(K236A), and Q251A (Q239A).substrate cleavage was measured by color development at 405 nm on a
Vmax Kinetic Microplate Reader.
All assays were performed at least three times with duplicate or
triplicate data points for all of the proteins except the AT time course
inhibition studies with the thrombin exosite-2 mutants, which were
done two times in triplicate. The second order rate constants of inhi-
bition were calculated as described previously [23,24].3. Results
3.1. Eﬀect of RNA aptamer to thrombin on serpin–thrombin
inhibition in the absence of glycosaminoglycans
In the absence of glycosaminoglycans, the addition of Tog-
gle-25 resulted in a signiﬁcant decrease (3-fold) in thrombin
inhibition by both AT and HCII, but a slight increase (1.4-
fold) in thrombin inhibition by PCI (Table 1). There was no
signiﬁcant change in thrombin inhibition by AT, HCII and
PCI in the presence of the control RNA aptamer BulgeUs
(Table 1). These results suggest that Toggle-25 (Mr  9000)
binding to thrombin, possibly by steric hindrance, alters inhi-
bition by serpins.
3.2. Eﬀect of RNA aptamer to thrombin on serpin–thrombin
inhibition in the presence of glycosaminoglycans
It is likely that aptamers will be generated to protein regions
with substantial charge, such as exosite-1 or exosite-2. To in-
vestigate the possibility that Toggle-25 binds to exosite-2, we
studied glycosaminoglycan-accelerated thrombin inhibition by
AT, HCII and PCI. In the presence of heparin, the addition of
Toggle-25 resulted in a substantial loss of inhibitory activity
for the AT–heparin and PCI–heparin inhibition reactions
(Fig. 1 and Table 1). There was only a slight decrease in in-
hibitory activity in the presence of Toggle-25 both with HCII–
heparin and with HCII–dermatan sulfate, consistent with the
fold-change in activity found in the absence of glycosamino-
glycan (Fig. 1 and Table 1). The control RNA aptamer
BulgeUs had no eﬀect on thrombin inhibition by serpin–gly-
cosaminoglycans (Fig. 1 and Table 1). To further evaluate
Toggle-25, we titrated in increasing amounts of the RNA
aptamer (from 0.01 to 10 nM) to thrombin (0.5 nM) and
measured the rate of inhibition by AT (5 nM)–heparin (500 ng/
mL, 0.1 units/ml, which is slightly less than the clinical range
of 0.3–0.7 units/ml). There was a 50% loss in the rate of
thrombin inhibition at 2 nM Toggle-25 (data not shown),
which is similar to the Kd reported previously for Toggle-25/
thrombin binding [16]. These results imply that Toggle-25 may
interact with the heparin-binding region of thrombin to reduce
serpin–glycosaminoglycan–thrombin complex formation,
thereby protecting thrombin from inhibition. They also imply
that Toggle-25 might neutralize heparin activity at relevant
therapeutic dosages.3.3. Mapping the binding site of the RNA aptamer to thrombin
exosite-2
Our results above implied that Toggle-25 might be inter-
acting with residues in the glycosaminoglycan-binding site of
thrombin (exosite-2). Therefore, a series of exosite-2 Ala-
scanned thrombin mutants were used in an attempt to localize
the Toggle-25 binding site. The rationale was that if speciﬁc
amino acids were responsible for Toggle-25 binding, these
thrombin mutants would be ‘‘resistant’’ to the RNA aptamer
and show no additional loss of activity. As the exosite-2
Table 2
Eﬀect of Toggle-25 during antithrombin inhibition of exosite-2 thrombin mu
Thrombin mutant No aptamera k2 (M1 min1) Plus To
Wild-type 1.97 105 0.64 1
R98A 2.10 105 2.01 1
E169A/K174A/D175A 1.60 105 1.42 1
R245A/K248A/Q251A 2.49 105 2.55 1
R245A 2.26 105 2.21 1
Q251A 2.05 105 0.58 1
Inhibition of thrombin and the exosite-2 thrombin mutants by AT was mea
aRate constants are the mean values of two separate determinations perform
Table 1
Eﬀect of Toggle-25 during thrombin inhibition by serpins in the absence and presence of glycosaminoglycans
Serpin/cofactor k2 (M1 min1)a
No aptamerb BulgeUs (control aptamer) Toggle-25 (thrombin aptamer)
AT 2.16 0.01 105 2.23 0.16 105 0.71 0.04 105
AT/Heparin 1.95 0.11 108 (900) 1.97 0.08 108(880) 0.04 0.003 108 (60)
HCII 1.99 0.11 104 1.90 0.10 104 0.71 0.09 104
HCII/Heparin 1.57 0.31 108 (7890) 1.52 0.28 108 (8000) 0.54 0.07 108 (7600)
HCII/DS 4.17 0.52 108 (20 950) 3.96 0.40 108 (20 840) 2.57 0.23 108 (36 200)
PCI 2.94 0.12 105 3.13 0.03 105 4.21 0.11 105
PCI/Heparin 5.85 0.33 106 (20) 5.95 0.09 106(19) 0.60 0.21 106 (1.4)
Inhibition of thrombin by AT, HCII and PCI was measured in the absence and in the presence of heparin or dermatan sulfate (DS), in the absence
and presence of Toggle-25 and control BulgeUs RNA aptamers. In the presence of glycosaminoglycans, the maximal inhibition of each curve was
used in the calculation of the average inhibition rate. Values are expressed as meansS.D. All assays were performed as described in Section 2.
aRate constants are the mean values of at least three separate determinations performed in duplicate or triplicate.
b Values in parentheses are the maximum fold-stimulation with glycosaminoglycan for AT-(5 lg/mL heparin), HCII-(200 lg/mL heparin and 500 lg/
mL dermatan sulfate) and PCI-(5 lg/mL heparin) thrombin inhibition reactions under the inhibition reactions condition used in Section 2.
Fig. 1. Inhibition of a-thrombin by heparin-binding serpins in the
presence of the RNA thrombin aptamer and in the presence of gly-
cosaminoglycans. Thrombin was incubated with AT (upper left panel),
PCI (upper right panel) and HCII (lower left and right panels) in the
presence of various amounts of glycosaminoglycans (heparin or der-
matan sulfate) in the absence of aptamer (d), and in the presence of 10
nM Toggle-25 aptamer (j) or control BulgeUs aptamer (m) as de-
scribed under Section 2. The data represent an average of at least three
separate assays performed in triplicate.
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arin, we only studied the eﬀect of Toggle-25 on the AT-
thrombin inhibition reaction in the absence of added heparin.
Of the nine exosite-2 thrombin mutants examined, ﬁve mutants
(R98A,E169A/K174A/D175A,R245A/K248A/Q251A,R245A,
and K248A) were resistant to Toggle-25, two mutants (D122A/
R123A/E124A and Q251A) resembled wild-type thrombin and
were altered by Toggle-25, and two thrombin mutants (R89A/
R93A/E94A and R178A/R180A/D183A) gave equivocal re-
sults, and while they may have had some resistance to the
aptamer there was substantial change even in the absence of
Toggle-25 (data not included). We then gathered more detailed
AT-thrombin inhibition data for the exosite-2 thrombin mu-
tants in the presence and absence of Toggle-25 to further im-
plicate speciﬁc residues (for instance, compare R245A/K248A/
Q251A to R245A and Q251A) (Table 2). These results suggest
that Toggle-25 binds at or near Arg 98, Glu 169, Lys 174, Asp
175, Arg 245, and Lys 248 in thrombin exosite-2 (Table 2),
which corresponds to residues in the glycosaminoglycan-
binding site of thrombin.4. Discussion
The speciﬁcity of thrombin aptamers provides a novel bio-
medical/biochemical tool to probe thrombin’s interactions
with macromolecular substrates. The thrombin aptamer de-
scribed by Bock and co-workers [25–27] is a potent anti-
thrombotic with aﬃnity to exosite-1, both in vitro and in vivo.
Aptamers have been prepared to both exosite-1 [25,26] and
exosite-2 [28] of thrombin. Toggle-25, with a KD of 2 nM,
was created to bind both human and porcine thrombin [16].tants







sured in the absence of heparin as described in Section 2.
ed in triplicate.
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teraction using heparin-binding serpins, which are important
regulators of thrombin activity in vivo. Using a set of Ala-
scanned thrombin mutants [21,29,30], our results suggest that
thrombin exosite-2 is involved in Toggle-25 binding (Fig. 2).
Another result of this study was the veriﬁcation of the crit-
ical need for exosite-2 for AT–heparin (900-fold versus 60-fold
acceleration in the absence and presence of Toggle-25, re-
spectively) and PCI–heparin (20-fold versus 1.4-fold accelera-
tion in the absence and presence of Toggle-25, respectively)
thrombin inhibition reactions, and a less important role for
exosite-2 during HCII–heparin (7900-fold versus 7600-fold
acceleration in the absence and presence of Toggle-25, re-Fig. 2. Space-ﬁlled molecular model of a-thrombin. The ﬁgure is a
CPK representation of the reﬁned 1.9 A crystal structure of human a-
thrombin (PDB ﬁle 1PPB*) and produced using Insight II software
(Accelrys, Inc., San Diego, CA). Upper panel: ‘‘traditional’’ front
view; lower panel: 180 rotation to the right of traditional view. As
identiﬁed in the assays performed (see Fig. 2 and Table 2), the residues
involved in Toggle-25 binding are shown in yellow, residues that were
equivocal are shown in light blue and the residues not involved are
highlighted in dark blue. The thrombin active site residues are seen in
red and the Phe-Pro-Arg-chloromethyl ketone is shown in orange.spectively) or HCII–dermatan sulfate (21 000-fold versus
36 000-fold acceleration in the absence and presence of Toggle-
25, respectively) interactions. These observations reinforce
other recent studies probing serpin–glycosaminoglycan/
thrombin interactions [31–35].
As Toggle-25 alters the AT– and HCII–thrombin inhibition
reactions in the absence of added glycosaminoglycan, the
aptamer must alter thrombin’s active site recognition of the
AT- and HCII-reactive site loop region. It is interesting to note
that the global nature of HCII and AT revealed by X-ray
crystallography is quite similar [36,37], and they both had the
same 3-fold loss of activity in the presence of Toggle-25/
thrombin (in the absence of glycosaminoglycan). The slight
increase in thrombin inhibition activity by PCI (with no added
heparin) with Toggle-25 is reminiscent of that seen with the
R89A/R93A/R98A thrombin mutant [38], and may represent a
subtle diﬀerence in the PCI-thrombin inhibition mechanism
compared to AT and HCII. A monoclonal antibody isolated
from a patient with multiple myeloma was recently shown to
be a potent anticoagulant [39,40]. This IgG’s anticoagulant
activity was partly due to an enhancing eﬀect during AT– and
HCII–thrombin inhibition reactions (in the absence of hepa-
rin), and the antibody’s binding site was mapped to thrombin
exosite-2 [39,40]. Thus, ligand binding (in this case, a RNA
aptamer compared to an IgG that binds exosite-2) to thrombin
at or near the same site can diﬀerentially promote conforma-
tions that inﬂuence protease activity.
Aptamers (RNA or DNA) are a promising new group of
compounds that have already found some utility and use in
regulating blood coagulation in vitro and in vivo [14–
17,26,41,42,43]. The objective of anticoagulant/antithrombotic
therapy in cardiovascular disease is to prevent further ﬁbrin
deposition and platelet aggregation, halting current and future
ischemic episodes [6]. While the most commonly used agents
(heparin, coumadin and aspirin) have well established bio-
logical actions, there are some limitations to their eﬀectiveness
and this has led to the development of new antithrombotic
compounds [6]. The results described here suggest that speciﬁc
RNA aptamers directed at exosite-2 of thrombin may be used
for many diﬀerent facets of therapeutic regulation of thrombin.
We have shown that Toggle-25 can reduce the eﬀect of heparin
on glycosaminoglycan-dependent thrombin inhibition by ser-
pins and could serve to regulate the anticoagulant eﬀect of
heparin in vivo. The notion of therapeutically using an apt-
amer like Toggle-25 becomes especially attractive when used in
conjunction with an antidote RNA aptamer [17], that can be
speciﬁcally targeted to Toggle-25 to reverse its action.
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